Page last updated: 2024-08-21

pyrazines and Carcinoma, Medullary

pyrazines has been researched along with Carcinoma, Medullary in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Masmiquel Comas, L; Nicolau Ramis, J1
Ain, KB; Fanourakis, G; Kotoula, V; McMillin, D; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V; Tseleni-Balafouta, S1
Delmore, JE; Hayden, P; Kotoula, V; McMillin, DW; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V1

Other Studies

3 other study(ies) available for pyrazines and Carcinoma, Medullary

ArticleYear
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:1

    Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms

2012
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Caspases; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Enzyme Inhibitors; Humans; Insulin-Like Growth Factor I; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-jun; Pyrazines; Thyroid Neoplasms; Tumor Suppressor Protein p53

2006
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Cell Line, Tumor; Colorimetry; Doxorubicin; Genes, bcl-2; Humans; Membrane Potentials; Oncogene Protein v-akt; Protease Inhibitors; Pyrazines; RNA, Neoplasm; Tetrazolium Salts; Thiazoles; Thyroid Neoplasms; Transcription, Genetic

2007